Methylenetetrahydrofolate reductase polymorphisms in myeloid leukemia patients from Northeastern Brazil
AUTOR(ES)
Barbosa, Cynara Gomes, Souza, Claudio Lima, Moura Neto, José Pereira de, Arruda, Maria da Glória Bomfim, Barreto, José Henrique, Reis, Mitermayer Galvão, Goncalves, Marilda Souza
FONTE
Genetics and Molecular Biology
DATA DE PUBLICAÇÃO
2008
RESUMO
Methylenetetrahydrofolate reductase (MTHFR: EC 1.5.1.20) polymorphisms are associated to acute lymphoid leukemia in different populations. We used the polymerase chain reaction and the restriction fragment length polymorphism method (PCR-RFLP) to investigate MTHFR C677T and A1298C polymorphism frequencies in 67 patients with chronic myeloid leukemia (CML), 27 with acute myeloid leukemia FAB subtype M3 (AML-M3) and 100 apparently healthy controls. The MTHFR mutant allele frequencies were as follows: CML = 17.2% for C677T, 21.6% for A1298C; AML-M3 = 22.2% for C677T, 24.1% for A1298C; and controls = 20.5% for C677T, 21% for A1298C. Taken together, our results provide evidence that MTHFR polymorphisms have no influence on the development of CML or AML-M3.
Documentos Relacionados
- Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults
- Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia
- Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase
- Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications
- Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil